Evidence map›Paper›PMID 40358969›Full record

ArticleJournal of biochemical and molecular toxicology2025

Pasireotide Exerts Anti-Inflammatory Effects in the Endothelium.

Saikat Fakir, Madan Sigdel, Md Matiur Rahman Sarker, Nektarios Barabutis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of biochemical and molecular toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Saikat FakirSchool of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana Monroe, Monroe, Louisiana, USA.ORCID https://orcid.org/0009-0007-4103-6260
Madan SigdelSchool of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana Monroe, Monroe, Louisiana, USA.
Md Matiur Rahman SarkerSchool of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana Monroe, Monroe, Louisiana, USA.
Nektarios BarabutisSchool of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana Monroe, Monroe, Louisiana, USA.ORCID https://orcid.org/0000-0001-8366-5099

Funding

Synthetic Somatostatin Analogs Protect Against Endothelial Barrier DysfunctionR03AI176433 · NIAID · UNIVERSITY OF LOUISIANA AT MONROE · PI BARABUTIS, NEKTARIOS · 2024 to 2025
$145k
Dr. Barabutis' research is supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number R03AI176433. The content is solely the responsibility of the author and does not necessarily represent the official views of the National Institutes of Health.NIAID NIH HHS R03 AI176433
6 · The paper itself

Abstract

Growth hormone (GH) modulates normal growth and metabolism, and its effects are counteracted by somatostatin (SST). Pasireotide (PAS), an FDA-approved synthetic derivative of somatostatin, acts via binding to multiple somatostatin receptors, and it is commonly used in conditions unresponsive to first-generation somatostatin analogs. Herein we explore the potential of PAS to protect against endothelial dysfunction induced by lipopolysaccharides (LPS). This is a bacterial toxin which causes inflammation and compromises endothelial barrier integrity. Endothelial cells were treated with PAS before LPS exposure to evaluate the corresponding effects on cell viability, inflammation, and barrier function. Since PAS suppressed LPS-triggered endothelial injury, it is suggested that this compound could be repurposed for endothelium-dependent disorder treatment.

Indexed as

Anti-Inflammatory AgentsEndothelial CellsEndothelium, VascularHuman Umbilical Vein Endothelial CellsSomatostatinCell SurvivalHumansInflammationLipopolysaccharidesAnti-Inflammatory AgentsLipopolysaccharidespasireotideSomatostatinhormoneinflammationreceptorsomatostatin

Identifiers

PMID40358969
PMCPMC12135819

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.